In its fourth and largest acquisition in the last 18 months, Ahmedabad-based Eris Lifesciences Ltd has acquired Strides Shasun Ltd‘s India branded generics business for a cash consideration of Rs 500 crore ($77 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
